Skip to content
type1.science
Phase 1Active, not recruitingNCT04590872

PIpepTolDC tolerogenic dendritic-cell vaccine

City of Hope phase 1 study of an autologous tolerogenic dendritic-cell vaccine loaded with proinsulin peptide in adults with type 1 diabetes, focused on manufacturing feasibility and safety.

Primary endpoints

  • Incidence of adverse events through 2 years
  • Number of successful manufactured vaccine products

Results so far

No efficacy results posted. Enrollment is complete (actual n=6). Primary completion 3 June 2024; the live registry is ACTIVE_NOT_RECRUITING with estimated study completion 15 December 2026. Completion of enrollment is not a posted manufacturing or C-peptide result.